We conducted a retrospective case series at Tawam Hospital (2019-2024), including patients with genetically confirmed MODY who received a Glucagon-like peptide-1 (GLP-1) receptor agonist or dual GLP-1/Glucose-dependent insulinotropic polypeptide (GIP) receptor agonist for at least three months. The gene discussed is GLP1R; the disease is MODY.